Advertisement

Methylphenidate Hydrochloride Extended Release Oral Presentations

[02 March 2016]

Products Affected - Description

Methylphenidate LA extended release capsule, Actavis
20 mg, 100 count (NDC 67767-0200-01) - discontinued
30 mg, 100 count (NDC 67767-0201-01) - discontinued
40 mg, 100 count (NDC 67767-0202-01) - discontinued
 
Methylphenidate LA extended release capsule, Teva
20 mg, 100 count (NDC 00093-5346-01)
30 mg, 100 count (NDC 00093-5347-01)
40 mg, 100 count (NDC 00093-5348-01)

Reason for the Shortage

  • Actavis states the shortage of methylphenidate was due to increased demand. Actavis discontinued methylphenidate LA 30 mg and 40 mg tablets in late-2015.
  • Janssen states the shortage of Concerta was due to increased demand.
  • Kremers Urban had Methylphenidate CD on allocation due to increased demand.
  • Mallinckrodt states the shortage was due to delay in obtaining raw materials.
  • Novartis discontinued Ritalin SR in October 2014.
  • Teva introduced generic methylphenidate extended release capsules (CD) in late-September 2012, and these capsules are AB-rated to Metadate CD capsules.
  • UCB states methylphenidate ER tablets were on shortage due to supply and demand.

Available Products

Concerta extended release tablet, Janssen
18 mg, 100 count (NDC 50458-0585-01)
27 mg, 100 count (NDC 50458-0588-01)
36 mg, 100 count (NDC 50458-0586-01)
54 mg, 100 count (NDC 50458-0587-01)
 
Metadate CD extended release capsule, UCB
10 mg, 100 count (NDC 53014-0579-07)
20 mg, 100 count (NDC 53014-0580-07)
30 mg, 100 count (NDC 53014-0581-07)
40 mg, 100 count (NDC 53014-0582-07)
50 mg, 100 count (NDC 53014-0583-07)
60 mg, 100 count (NDC 53014-0584-07)
 
Metadate ER extended release tablet, UCB
20 mg, 100 count (NDC 53014-0594-01)
 
Methylphenidate CD extended release capsule, Kremers Urban
10 mg, 100 count (NDC 62175-0151-37)
20 mg, 100 count (NDC 62175-0152-37)
30 mg, 100 count (NDC 62175-0153-37)
40 mg, 100 count (NDC 62175-0154-37)
50 mg, 100 count (NDC 62175-0155-37)
60 mg, 100 count (NDC 62175-0156-37) 
 
Methylphenidate CD extended release capsule, Teva
10 mg, 100 count (NDC 00093-5295-01)
20 mg, 100 count (NDC 00093-5296-01)
30 mg, 100 count (NDC 00093-5297-01)
40 mg, 100 count (NDC 00093-5298-01)
60 mg, 100 count (NDC 00093-5293-01)
50 mg, 100 count (NDC 00093-5292-01)
 
Methylphenidate LA extended release capsule, Actavis
20 mg, 100 count (NDC 45963-0200-11)
 
Ritalin LA extended release capsule, Novartis
10 mg, 100 count (NDC 00078-0424-05)
20 mg, 100 count (NDC 00078-0370-05)
30 mg, 100 count (NDC 00078-0371-05)
40 mg, 100 count (NDC 00078-0372-05)
60 mg, 100 count (NDC 00078-0658-15)
 
Methylphenidate extended release tablet, Actavis
18 mg, 100 count (NDC 00591-2715-01)
27 mg, 100 count (NDC 00591-2716-01)
36 mg, 100 count (NDC 00591-2717-01)
54 mg, 100 count (NDC 00591-2718-01)
 
Methylphenidate extended release tablet, Kremers Urban
18 mg, 100 count (NDC 62175-0310-37)
27 mg, 100 count (NDC 62175-0311-37)
36 mg, 100 count (NDC 62175-0312-37)
54 mg, 100 count (NDC 62175-0313-37)
 
Methylphenidate extended release tablet, Mallinckrodt
10 mg, 100 count (NDC 00406-1445-01)
20 mg, 100 count (NDC 00406-1473-01)
27 mg, 100 count (NDC 00406-0127-01)
36 mg, 100 count (NDC 00406-0136-01)
54 mg, 100 count (NDC 00406-0154-01)

Estimated Resupply Dates

Teva has all methylphenidate LA extended release capsules on temporarily unavailable and the company cannot estimate when product will return.

Related Shortages

Updated

March 2, 2016; December 22 and 16, September 10, June 1, May 26 and 6, March 23 and 4, February 19 and 4, January 23 and 9, 2015; December 18, 10 and 3, November 5, October 10, September 24 and 10, August 15, June 23 and 5, April 15, March 27, February 11, January 17, 2014; November 14, October 17, September 23, 16 and 12, August 28 and 13, July 29, 11 and 3, June 20 and 7, May 22 and 15, April 5, March 8 and 5, February 22, January 24, 2013; November 30 and 2, October 1, September 12, July 18, June 25, May 17, April 23, March 8, February 17, January 30 and 13, 2012; December 14 and 1, October 19 and 6, September 21, August 3, July 6, June 23 and 6, May 19, 13 and 5, April 8, March 23 and 8, 2011, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing